CA-MARY-KAY-INC.
20.5.2021 19:05:09 CEST | Business Wire | Press release
What started out as a way for the style community to come together when the pandemic stopped the industry in its tracks has grown into one of the largest gatherings of the fashion industry worldwide. Now, with life opening back up in the US and abroad, Glamhive ’s Digital Spring Style and Beauty Summit on May 22nd will be the final 100% digital summit. Glamhive will launch all future events as a hybrid physical-digital experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005908/en/
The Spring Summit will be the company’s fifth global digital experience and will once again bring together industry professionals and beauty and style enthusiasts to discuss spring style, skincare in the colder months, getting started in the fashion business and much more.
The all-day, ticketed event will feature 19 panels with 66-plus speakers. Below is an overview of the topics that will be covered by the all-star speaker line-up.
TOPICS:
- Who Made This? How Sustainably Sourced Products Empower Women With Every Purchase
- Style 411: Inside the World of Styling
- Contemporary Costume Design: The Role, The Challenges, And It’s Influence On Fashion
- The Red Carpet Report
- “A Star Is Born” Exclusive Interview with Astrologist Susan Miller
- Exclusive Interview with Bridgerton’s Costume Designer Ellen Mirojnick
- How To Make A Great First Impression Every Time
- Brand Building for Creatives & Entrepreneurs
During the Who Made This? How Sustainably Sourced Products Empower Women With Every Purchase panel, Chief Marketing Officer for Mary Kay Inc., Sheryl Adkins-Green, will host a discussion on the origin of the items inside each of our closets—and how we can better know the innovators behind the fashion styles. Panelists include Jane Mosbacher, Founder and CEO of TO THE MARKET; Matilda Payne Boakye-Ansah, Designer, Eco-Warrior, Social Entrepreneur, Founder of MH Couture and Co-Founder of Xtreme Upcycle; Christelle C. Paul, Founder and Director of Atelier Calla; and Tara Swennen, celebrity stylist.
“We have an opportunity every day to make choices that help protect our environment,” said Sheryl Adkins-Green, “and it’s important to know about the people and products that are making a difference.”
CO-HOSTS
Stephanie Sprangers - Founder & CEO, Glamhive
Johnny Wujek - Celebrity Stylist & Costume Designer to Katy Perry and Mariah Carey
Nicole Chavez - Celebrity Stylist to Kristen Bell and Jessica Simpson
Andrew Fitzsimons - Celebrity hairstylist to The Kardashians
Claire Sulmers - Founder + CEO of Fashion Bomb Daily
SPEAKERS:
Our speakers are celebrity stylists, makeup artists, and image-makers who work with the biggest names in Hollywood and beyond, including Kristen Stewart, Angelina Jolie, Matthew McConaughey, Emily Blunt, Gabrielle Union, Zendaya, Sophie Turner, Amanda Seyfried, Margot Robbie, Lupita Nyong’o, Emma Watson, Rosie Huntington-Whiteley, Claire Danes, Carmen Electra.
CELEBRITY STYLISTS:
Jen Rade, Tara Swennen, Jessica Paster, Nicole Chavez, Sonia Young, Dana Asher Levine, Mimi Lombardo, Joiee Thorpe, Franzy Staedter.
CELEBRITY MAKEUP ARTISTS + HAIRSTYLISTS:
Sheridan Ward, Matey Denno, Matin Maulawizada, Christian Wood, Halley Brisker, Larry Sims
MODERATORS:
Brian Underwood (Oprah Magazine), Brooke Jaffe, (Penske Media), Alexis Bennett (Vogue), Sarah Ball (PEOPLE Magazine), Flavia Nunez (Real Simple), Alana Peden (StyleCaster) and Sheryl Adkins-Green (Mary Kay Inc.)
Tickets to the conference are $149 for an all-day ticket. Presenting sponsor for the Glamhive Digital Spring Style and Beauty Summit is Mary Kay Inc. and its Mary Kay Global Design Studio.
For more information, visit https://www.glamhive.com/live
About Glamhive: Glamhive was founded by entrepreneur Stephanie Sprangers in 2017 with the vision to democratize personal styling and the premise that the confidence that comes with glamour should not be exclusive to the rich and famous.
The online styling experience offers anyone with a WiFi connection access to stylists who will provide them with the support they need to be the best version of themselves. For stylists, it is a seamless end-to-end platform to help them grow their network and their business, 100% virtually.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005908/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom